Contrasting responses of non-small cell lung cancer to antiangiogenic therapies depend on histological subtype

The vascular endothelial growth factor (VEGF) pathway is a clinically validated antiangiogenic target for non-small cell lung cancer (NSCLC). However, some contradictory results have been reported on the biological effects of antiangiogenic drugs. In order to evaluate the efficacy of these drugs in...

Descripción completa

Detalles Bibliográficos
Autores principales: Larrayoz, Marta, Pio, Ruben, Pajares, María J, Zudaire, Isabel, Ajona, Daniel, Casanovas, Oriol, Montuenga, Luis M, Agorreta, Jackeline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Backwell Publishing Ltd 2014
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3992079/
https://www.ncbi.nlm.nih.gov/pubmed/24500694
http://dx.doi.org/10.1002/emmm.201303214

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3992079/
https://www.ncbi.nlm.nih.gov/pubmed/24500694
http://dx.doi.org/10.1002/emmm.201303214

Ejemplares similares